Chinese Companies Progress Peptide Fusion Inhibitors For COVID-19
Executive Summary
China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.
You may also be interested in...
Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads
Chinese pharma firms led by Kelun are moving fast to develop the next-generation of cytotoxic "warheads," a key component of antibody-drug conjugates, disclosed company executives at conference in Suzhou.
China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
Allorion Rides Unconventional Discovery Platforms To Major Funding
Allorion's key innovative attractions include discovery platforms for allosteric inhibitor screening and the discovery of synthetic lethality targets/molecules, along with a small but growing pipeline of novel assets. Founded in 2020, the China- and US-based biotech has now raised more than $100m in three financing deals, including a $50m series B.